Teladoc Health Executive Compensation (FY25)
TDOC · New York, NY · Executive and director compensation, fiscal 2022 to 2025
The Teladoc Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): May 21, 2026
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
257 figures on this page: 251 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Charles Divita, III: $16,061,267 → $11,202,996 (30.2% lower)
Say-on-pay support: 73.4% → 88.8% (15.4 points higher)
CEO pay ratio: 201:1 → 127.6:1 (36.5% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Teladoc Health's chief executive and what were they paid?
Charles Divita, III was paid $11,202,996 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $16,061,267 reported for fiscal 2024, Divita, III's total was 30.2% lower.
What was Teladoc Health's say-on-pay result?
Shareholders supported the say-on-pay proposal with 88.8% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
Which companies are in Teladoc Health's peer group?
Companies named in the disclosed peer group include Agilon Health, Inc., Alignment Healthcare, Inc., AMN Healthcare Services, Inc., Astrana Health, Inc. and Aveanna Healthcare Holdings Inc., among others.
What is Teladoc Health's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 127.6:1, against median employee compensation of $87,811.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jason Gorevic Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mala Murthy Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Claus Jensen Chief Innovation Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Laizer Kornwasser President, Enterprise Growth and Global Markets | ◇ | ◇ | ◇ | — | ◇ | — | — | ◇ |
Michael Waters Chief Operating Officer | ◇ | ◇ | ◇ | — | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Charles Divita, III Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Gorevic Former Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mala Murthy Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Waters Former Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Laizer Kornwasser Former President, Enterprise Growth and Global Markets Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Carlos Nueno President, International | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Adam C. Vandervoort Chief Legal Officer and Secretary | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Kelly Bliss President, U.S. Group Health | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Charles Divita, III Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mala Murthy Former Chief Financial Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Carlos Nueno President, International | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Kelly Bliss President, U.S. Group Health | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Adam Vandervoort Chief Legal Officer and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Adam C. Vandervoort | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Adam C. Vandervoort | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Carlos Nueno | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Carlos Nueno | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Charles Divita III | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Charles Divita III | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Kelly Bliss | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kelly Bliss | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
| Mala Murthy | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mala Murthy | PSU | ◇ | — | ◇ | ◇ | ◇ | — | ◇ |
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Charles Divita | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Kelly Bliss | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Adam Vandervoort | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Carlos Nueno | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Kelly Bliss
President, U.S. Group Health · Terms as described in the company’s compensation discussion · dated July 14, 2017
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
David B. Snow, Jr | ◇ | ◇ | — | — | — | — | ◇ |
Kenneth H. Paulus Board chair | ◇ | ◇ | — | — | — | — | ◇ |
J. Eric Evans | ◇ | ◇ | — | — | — | — | ◇ |
David L. Shedlarz | ◇ | ◇ | — | — | — | — | ◇ |
Thomas G. McKinley | ◇ | ◇ | — | — | — | — | ◇ |
Mark Douglas Smith, M.D., MBA | ◇ | ◇ | — | — | — | — | ◇ |
Catherine A. Jacobson | ◇ | ◇ | — | — | — | — | ◇ |
Sandra L. Fenwick | ◇ | ◇ | — | — | — | — | ◇ |
Charles Divita, III, Michael S. Smith and Susan R. Salka served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee member | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Agilon Health, Inc. AGL
- Alignment Healthcare, Inc. ALHC
- AMN Healthcare Services, Inc. AMN
- Astrana Health, Inc. ASTH
- Aveanna Healthcare Holdings Inc. AVAH
- Clover Health Investments, Corp. CLOV
- DocuSign, Inc. DOCU
- Dropbox, Inc. DBX
- Euronet Worldwide, Inc. EEFT
- Evolent Health, Inc. EVH
- Maximus Inc. MMS
- Medpace, Inc. MEDP
- Nutanix, Inc. NTNX
- OpenText Corporation symbol not shown
- Pediatrix Medical Group, Inc. MD
- Premier Inc. PINC
- Privia Health Group, Inc. PRVA
- RingCentral, Inc. RNG
- Twilio Inc. TWLO
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 22, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 26, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 17, 2021 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Teladoc Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Teladoc Health sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
257 figures on this page: 251 cited to the filing that reported them, 6 calculated from figures it prints.
251 cited to the filing
6 calculated from the filing
Documents cited
- 0001477449-26-000030Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001477449-26-0000202025 Director compensation table · 2025 Grants of Plan-Based Awards Table · 2025 Outstanding equity awards at fiscal year-end table · 2025 Summary Compensation Table · and 3 more sections
- 0001477449-25-000063Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001477449-25-0000402024 Summary compensation table
- 0001477449-25-000005EX-10.45
- 0001477449-24-000122Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001104659-23-066013
- 0001104659-23-0440312022 SUMMARY COMPENSATION TABLE · 2022 Summary Compensation Table
- 0001104659-22-067619
- 0001104659-21-068841Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Teladoc Health executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/TDOC (accessed 2026).
Short form: data: Velarion
The Teladoc Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Teladoc Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Teladoc Health discloses
The companies named in TDOC's own disclosed peer group.
Agilon Health, Inc.Alignment Healthcare, Inc.AMN Healthcare Services, Inc.Astrana Health, Inc.Aveanna Healthcare Holdings Inc.Clover Health Investments, Corp.DocuSign, Inc.Dropbox, Inc.Euronet Worldwide, Inc.Evolent Health, Inc.Maximus Inc.Medpace, Inc.Nutanix, Inc.Pediatrix Medical Group, Inc.Premier Inc.Privia Health Group, Inc.RingCentral, Inc.Twilio Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}